TransCode Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
All proposals, including stock issuances, director elections, stock plan amendment, and auditor ratification, were approved by majority vote. No questions were raised during the Q&A session.
-
The meeting was called to order, a quorum was confirmed, and the Inspector of Election was appointed. The meeting was adjourned to allow time for Nasdaq to complete its review of the company's initial listing application, with the reconvened meeting scheduled for July 20, 2026.
Fiscal Year 2025
-
The meeting confirmed a quorum, elected four directors, and approved all proposals, including an increase in stock options and auditor ratification. A shareholder Q&A addressed clinical trial participation, with further results expected in September.
-
A quorum was established and two proposals—a reverse stock split and potential adjournment—were approved by majority vote. Stakeholders' questions focused on clinical trial data reporting and NIH grant funding, with assurances of timely updates and no current funding impact.